FDA Receives Submission for Hemophilia A Drug BAX 855
January 5th 2015The US Food and Drug Administration recently announced it had received a submission for a biologics license application from Nektar Therapeutics and Baxter International Inc for an investigational, extended half-life recombinant factor VIII treatment for hemophilia A.
Read More
Prediction Ratios for Atherosclerosis Cardiovascular Disease Factors Do Not Match Actual Use
December 17th 2014Attempts to calibrate statin use, revascularization procedures, and the underascertainment of atherosclerosic cardiovascular disease have not matched the current prediction ratios.
Read More